Frank McCormick

Leidos (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

129h-index80.2kcitations786works4.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Kinase Regulation and GTPase Signaling(167), Cancer-related Molecular Pathways(106), Melanoma and MAPK Pathways(103), PI3K/AKT/mTOR signaling in cancer(100), Virus-based gene therapy research(54)

Publications785 total

Abstract A063: BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models
Molecular Cancer Therapeutics·2025
Abstract C082: BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia
Molecular Cancer Therapeutics·2025
Dynamics and lipid membrane coupling of the RAS-RAF complex revealed via multiscale simulations
Biophysical Journal·2025Open Access
Molecular glues that facilitate RAS binding to PI3Kα promote glucose uptake without insulin
Science·2025· 7 cited
A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system
Proceedings of the National Academy of Sciences·2025Open Access
Abstract PS7-04: BBO-10203, a first-in-class, orally bioavailable, selective blocker of the PI3Kα:RAS interaction inhibits tumor growth alone and in combination with standard of care therapies in breast cancer models without inducing hyperglycemia
Clinical Cancer Research·2025· 1 cited
BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction
Science·2025· 13 cited
435 | INTEGRATED GENE EXPRESSION AND PATHWAY ENRICHMENT ANALYSES FOLLOWING CDK9 INHIBITION IN CUTANEOUS T‐CELL LYMPHOMA PATIENT‐DERIVED XENOGRAFT MODELS
Hematological Oncology·2025Open Access
Blocking C-terminal processing of KRAS4b via a direct covalent attack on the CaaX-box cysteine
Proceedings of the National Academy of Sciences·2025· 3 citedOpen Access
NMR 1H, 13C, and 15N resonance assignments of the oncogenic Q61R variant of human NRAS in the active, GTP-bound conformation
Biomolecular NMR Assignments·2025Open Access
Abstract 3788: BBO-8520, a first-in-class direct dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C, exhibits robust efficacy in non-small cell lung cancer preclinical models
Cancer Research·2025
Abstract 4368: Selective targeting of oncogenic KRAS G12D using complementary peptide nucleic acid oligomers
Cancer Research·2025· 1 cited
Abstract 4378: BBO-11818, an orally bioavailable, highly potent and non-covalent pan-KRAS inhibitor demonstrates robust anti-tumor activity in KRAS-mutant preclinical models
Cancer Research·2025· 4 cited
Abstract 1765: RPT1G, a first-in-class hyperbolic NAMPT inhibitor that avoids on-target toxicity
Cancer Research·2025
Abstract 4226: Genome-wide CRISPRi screening identifies histone modification as a synergistic partner with JAK/STAT inhibition for enhancing anti-tumor activity in CTCL, validated in PDX-derived tumor cells
Cancer Research·2025
Selective targeting of oncogenic KRAS G12D using peptide nucleic acid oligomers attached to cell-penetrating peptides
2025Open Access
Supplementary Figure S6 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRAS<sup>G12C</sup>
2025Open Access
Supplementary Table S2 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRAS<sup>G12C</sup>
2025Open Access
Supplementary Figure S2 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRAS<sup>G12C</sup>
2025Open Access
Supplementary Figure S3 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRAS<sup>G12C</sup>
2025Open Access
page 1 of 40Next →

Frequent Co-authors

George A. Martin(5), Joe W. Gray(4), David Stokoe(4), Gideon Bollag(4), Marc Symons(4), Osamu Tetsu(3), Henry R. Bourne(3), David H. Kirn(3), D.A.R. Sanders(2), Ilya Shmulevich(2), Thomas J. Giordano(2), Richard M. Neve(2), Nora Bayani(2), Paul T. Spellman(2), Donna G. Albertson(2), Stephen P. Ethier(2), Angelica Williams(2), Carla Heise(2), Adam Sampson-Johannes(2), Meg Trahey(2)